|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-4
|
|
pubmed:abstractText |
Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:ChandrasekarPranatharthiP,
pubmed-author:CorcoranGavinG,
pubmed-author:DonowitzGerald RGR,
pubmed-author:GogateJagadishJ,
pubmed-author:GraybillRichardR,
pubmed-author:GreeneReginald ERE,
pubmed-author:HachemRayR,
pubmed-author:HadleySusanS,
pubmed-author:HardaloCatherineC,
pubmed-author:HerbrechtRaoulR,
pubmed-author:KrishnaGopalG,
pubmed-author:LangstonAmeliaA,
pubmed-author:LouieArnoldA,
pubmed-author:PattersonThomas FTF,
pubmed-author:PediconeLisaL,
pubmed-author:PerfectJohn RJR,
pubmed-author:RaadIssamI,
pubmed-author:RibaudPatriciaP,
pubmed-author:SegalBrahm HBH,
pubmed-author:StevensDavid ADA,
pubmed-author:WalshThomas JTJ,
pubmed-author:WhiteCharles SCS,
pubmed-author:van BurikJo-Anne HJA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2-12
|
|
pubmed:dateRevised |
2007-9-6
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
|
|
pubmed:affiliation |
Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892, USA. walsht@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
